724 related articles for article (PubMed ID: 17375304)
1. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Shin SJ; Ahn JB; Choi HJ; Cho BC; Jeung HC; Rha SY; Chung HC; Roh JK
Cancer Chemother Pharmacol; 2008 Jan; 61(1):75-81. PubMed ID: 17375304
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Choi DR; Yoon SN; Kim HS; Kim JH; Kim KY; Kim BC; Choi YK; Kim JB; Han B; Song HH; Zang DY
Cancer Chemother Pharmacol; 2015 Mar; 75(3):639-43. PubMed ID: 25630415
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Santini D; Vincenzi B; La Cesa A; Caricato M; Schiavon G; Spalletta B; Di Seri M; Coppola R; Rocci L; Tonini G
Oncology; 2005; 69(1):27-34. PubMed ID: 16088232
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y; Ohnuma H; Hirakawa M; Takahashi M; Osuga T; Okagawa Y; Murase K; Takada K; Kawano Y; Iyama S; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Okita K; Mizuguchi T; Furuhata T; Hirata K; Kato J
Cancer Chemother Pharmacol; 2015 Mar; 75(3):587-94. PubMed ID: 25577134
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Zhou JF; Bai CM; Cheng YJ; Jia N; Shao YJ; Chen SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun; 31(3):358-61. PubMed ID: 19621525
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Meyerhardt JA; Zhu AX; Enzinger PC; Ryan DP; Clark JW; Kulke MH; Earle CC; Vincitore M; Michelini A; Sheehan S; Fuchs CS
J Clin Oncol; 2006 Apr; 24(12):1892-7. PubMed ID: 16622264
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.
Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D
Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Li W; Xu J; Shen L; Liu T; Guo W; Zhang W; Chen Z; Zhu X; Li J
BMC Cancer; 2014 Dec; 14():986. PubMed ID: 25527007
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
13. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Vasile E; Masi G; Fornaro L; Cupini S; Loupakis F; Bursi S; Petrini I; Di Donato S; Brunetti IM; Ricci S; Antonuzzo A; Chiara S; Amoroso D; Andreuccetti M; Falcone A
Br J Cancer; 2009 Jun; 100(11):1720-4. PubMed ID: 19436300
[TBL] [Abstract][Full Text] [Related]
15. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Haller DG; Rothenberg ML; Wong AO; Koralewski PM; Miller WH; Bodoky G; Habboubi N; Garay C; Olivatto LO
J Clin Oncol; 2008 Oct; 26(28):4544-50. PubMed ID: 18824706
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Choi CK; Chan RT; Tung SY; Lui L; Siu S; Au GK; Ho JW; Law WL
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):168-75. PubMed ID: 18155454
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Souglakos J; Kalykaki A; Vamvakas L; Androulakis N; Kalbakis K; Agelaki S; Vardakis N; Tzardi M; Kotsakis AP; Gioulbasanis J; Tsetis D; Sfakiotaki G; Chatzidaki D; Mavroudis D; Georgoulias V
Ann Oncol; 2007 Feb; 18(2):305-10. PubMed ID: 17079693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
